Clinical trial
A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
NCT05660395 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
- Lead sponsor
- ADC Therapeutics S.A.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- July 28, 2023
- Completion date
- June 25, 2026
- Enrollment
- 5 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b-cell lymphoma, high-grade b-cell lymphoma